Azure™ with BlueSync™ Technology Improves Device Longevity and
Provides Automatic, Wireless Remote Patient Monitoring
India Medtronic Private
Limited, a wholly owned subsidiary of Medtronic
Plc (NYSE:MDT), today announced the launch of the Azure™
pacemaker with BlueSync™ technology – India’s first and only pacemaker that can
communicate directly with patients’ smartphones and tablets. The latest
addition to Medtronic’s Cardiac Rhythm & Heart Failure portfolio in
Azure features
Medtronic-exclusive BlueSync technology, which enables automatic, secure
wireless communication via Bluetooth Low Energy and remote monitoring via the
Medtronic CareLink™ Network, providing more timely alerts of clinically
relevant patient events that can be reviewed by a clinician at any time.
Security controls implemented and validated on BlueSync enabled devices include
access restrictions to protect integrity of device functionality and end-to end
encryption to protect patient data.
Atrial fibrillation (AF) is
an irregular, rapid heart rate that may cause symptoms like heart palpitations,
fatigue, and shortness of breath. AF occurs when the upper chambers of the
heart (atria) beat out of rhythm. As a result, blood is not pumped efficiently
to the rest of the body, causing an unusually fast heart rate, quivering, or
thumping sensations in the heart.
“The launch of Azure, our
most advanced pacemaker, is testament to our commitment toward re-imagining
innovation and delivering improved outcomes while reducing the burden on healthcare
systems. The pacemaker communicates directly and securely with the MyCareLink
Heart™ mobile app - an important advancement in the ongoing quest to constantly
monitor patient condition remotely. Remote monitoring of heart conditions
allows patients to receive expert medical advice from their physician while at
home or traveling instead of making multiple trips to the hospital. It is a
boon for heart patients and caregivers, especially in situations such as the
COVID-19 pandemic, providing peace of mind and freedom,” said Madan Krishnan,
Vice President, India Medtronic Pvt Ltd and Minimally Invasive Therapies Group
APAC.
MUMBAI,